Santhera Submits NDA in South Korea for Raxone® for the Treatment of LHON


12.06.18 07:00
Meldung
 
Santhera Submits NDA in South Korea for Raxone® for the Treatment of LHON

Santhera Pharmaceuticals Holding AG /Santhera Submits NDA in South Korea for Raxone® for the Treatment of LHON. Processed and transmitted by Nasdaq Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Pratteln, Switzerland, June 12, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces that the Korean Ministry of Food and Drug Safety (MFDS) has accepted for review Santhera's new drug application (NDA) for Raxone® (idebenone) for the treatment of Leber's hereditary optic neuropathy (LHON). Raxone was granted orphan drug designation for LHON in South Korea.



Raxone® (idebenone) is an oral medication, currently authorized in the European Union, Norway, Iceland, Liechtenstein and Israel at a daily dose of 900 mg for the treatment of visual impairment in adolescent and adult patients with LHON. It is the first and only medicine approved for this rare inherited disease which, if untreated, invariably leads to profound vision loss and blindness.



The NDA now submitted to the MFDS was prepared on the basis of the European marketing authorization and Santhera expects a decision from the South Korean drug regulatory authorities in approximately one year.



"The regulatory submission of Raxone for LHON in South Korea, one of the major Asian markets, underlines our geographical expansion and our commitment to providing treatment to patients worldwide, addressing a major unmet medical need in this rare disease," said Thomas Meier, PhD, CEO of Santhera.



Raxone has also been granted orphan drug designation for LHON in South Korea, which provides up to 10 years market exclusivity from the date of approval.



About Leber's Hereditary Optic Neuropathy and the Therapeutic Use of Raxone

Leber's hereditary optic neuropathy (LHON) is a heritable genetic disease causing profound vision loss and blindness. The disease presents predominantly in young, otherwise healthy adult males as rapid, painless loss of central vision, usually leading to permanent bilateral blindness within a few months of the onset of symptoms. About 95% of patients harbor one of three pathogenic mutations of the mitochondrial DNA, which cause a defect in the complex I subunit of the mitochondrial respiratory chain. This defect leads to decreased cellular energy (ATP) production, increased reactive oxygen species (ROS) production and retinal ganglion cell dysfunction, which cause progressive loss of visual acuity and blindness.



Raxone (idebenone), a synthetic short-chain benzoquinone and a cofactor for the enzyme NAD(P)H:quinone oxidoreductase (NQO1), circumvents the complex I defect, reduces and scavenges ROS, restores cellular energy levels in retinal ganglion cells and promotes recovery of visual acuity. Current data demonstrate that up to 50% of patients benefit from treatment and are protected from progression of visual acuity loss or experience a clinically relevant recovery of visual acuity.



Raxone for the treatment of LHON was granted orphan drug status in the EU, US, Switzerland and South Korea.



About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for orphan and other diseases with high unmet medical needs. The portfolio comprises clinical stage and marketed treatments for neuro-ophthalmologic, neuromuscular and pulmonary diseases. The most advanced pipeline product, idebenone, is in clinical Phase III for the treatment of Duchenne muscular dystrophy (DMD). Santhera's Raxone® (idebenone) is authorized in the European Union, Norway, Iceland, Liechtenstein and Israel for the treatment of Leber's hereditary optic neuropathy (LHON) and currently commercialized in more than 20 countries. For further information, please visit www.santhera.com.



Raxone® is a trademark of Santhera Pharmaceuticals.



For further information please contact:

public-relations@santhera.com or

Eva Kalias, Head External Communications

Phone: +41 79 875 27 80

eva.kalias@santhera.com



For Investors:

investor-relations@santhera.com or

Christoph Rentsch, Chief Financial Officer                                  Hans Vitzthum, LifeSci Advisors

Europe: +41 61 906 89 65                                                                US: +1 212 915 2568

christoph.rentsch@santhera.com                                                hans@lifesciadvisors.com



Disclaimer / Forward-looking statements

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

# # #

News Release Raxone LHON South Korea






This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Santhera Pharmaceuticals Holding AG via Globenewswire


--- End of Message ---



Santhera Pharmaceuticals Holding AG

Hohenrainstrasse 24 Pratteln Switzerland



ISIN: CH0027148649;





 

Breaking News


Kurs- und weitere Informationen zum Thema:

Santhera Pharmaceuticals Holding

Aktuelle Diskussionen zum Thema:

Santhera Pharma = Massivst ... (06.09.19)

Aktuelle Nachrichten zum Unternehmen:

Santhera: Vamorolone droht zu sc. (01.10.19)
Santhera: 105-Millionen-Geldregen d. (23.05.19)
Santhera: Das macht sprachlos! (24.04.19)
Santhera: Sind Sie dafür gewappne. (17.04.19)
SantheraWohin geht die Reise, ? (09.04.19)

Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

Santhera Pharmaceuticals Holding
Weitere Meldungen
 
13.06 Herantis Pharma announces .
13.06 Sanofi : Sanofi successfully.
13.06 TiGenix announces a change.
13.06 WISeKey launches an Speci.
13.06 WISeKey to Present at the.
13.06 ERAMET Group: Offer for .
12.06 Ad hoc: Hawesko Holding A.
12.06 XPO Logistics Honors Driver.
12.06 Ad hoc: CO.DON AG: CO.D.
12.06 Ad hoc: mybet Holding SE .
12.06 Ad hoc: LS telcom AG: Be.
12.06 Orange Belgium increased it.
12.06 Pöyry PLC: Pöyry's pro for.
12.06 Ad hoc: Aladdin Blockchain .
12.06 Automotive company commit.
12.06 Volta Finance Limited : Earl.
12.06 KBC Group: Update regardin.
12.06 Ahold Delhaize share buybac.
12.06 Van Lanschot Kempen: upda.
12.06 ForFarmers N.V.: ForFarmer.
12.06 Santhera reicht Zulassungsan.
12.06 Santhera Submits NDA in S.
12.06 IMCD to acquire US specialt.
12.06 Ad hoc: PEH Wertpapier A.
11.06 Ad hoc: Solvesta AG: Aufs.
11.06 EQS-Adhoc: AEVIS VICTOR.
11.06 Ad hoc: SHS VIVEON AG:.
11.06 Ad hoc: Timeless Homes Gm.
11.06 Ad hoc: Timeless Hideaways.
11.06 VP Human Resources leave.


Umfrage
 
Welche Social Networks nutzen Sie meistens?
Facebook
keine
Twitter
Xing
Linked in
Youtube
myspace
Google+
Wikipedia
andere


Stimmen: 57988 , Ergebnis


Kurssuche
Status: nicht eingeloggt

Registrieren | Passwort vergessen?
 
 
Im Bereich Nachrichten:
Daimler: Kursziel runter!
Experte: Stefan Hofmann, STOCK-WORLD
Kolumnen
K+S im Check!
Robert Sasse, (12:07)
Experte: Robert Sasse,
Börsengeflüster: #LONZA - ...
WIRTSCHAFTSINFORM., (12:06)
Experte: WIRTSCHAFTSINFORMATION .,
Barrick verkauft Super Pit-...
Björn Junker, GOLDINVEST.de (11:56)
Experte: Björn Junker, GOLDINVEST.de
Gold: Die Erholungsphase ...
Martin Chmaj, (11:43)
Experte: Martin Chmaj,
Australische Goldaktien ...
Martin Siegel, STABILITAS FONDS (11:20)
Experte: Martin Siegel, STABILITAS FONDS
Nemetschek-Aktie: Das darf ...
Volker Gelfarth, (11:09)
Experte: Volker Gelfarth,
FMC-Calls mit 64%-Chance ...
Walter Kozubek, (11:00)
Experte: Walter Kozubek,
K+S – 40 Prozent für ...
Feingold-Research, (10:57)
Experte: Feingold-Research,
Daimler: Kursziel runter!
Stefan Hofmann, STOCK-WORLD (10:26)
Experte: Stefan Hofmann, STOCK-WORLD
Puma legt einen Sprint ein!
S. Feuerstein, Hebelzertifikate-Trader (09:21)
Experte: S. Feuerstein, Hebelzertifikate-Trader
DAX Analyse: Die Bullen ...
X-markets Team, Deutsche Bank (09:04)
Experte: X-markets Team, Deutsche Bank
Henkel - Long-Chance nach ...
Christian Zoller, www.boerse-daily.de (08:48)
Experte: Christian Zoller, www.boerse-daily.de
Niquet's World
Neues vom Portal
 
Wie kann man bestimmen, dass ein Online-Casino unzuverlässig ist?
Letzte Börsen-Meldung
 
Letzte Börsen-Analyse
 
Top-Klicks News
 
Top-Klicks Analysen